866-997-4948(US-Canada Toll Free)

Prostate Cancer - Germany Drug Forecasts and Treatment Analysis to 2020

Published By :

GlobalData

Published Date : Nov 2010

Category :

Cancer

No. of Pages : 203 Pages



GlobalData's pharmaceutical report, Prostate Cancer Germany Drug Forecasts and Treatment Analysis to 2020. The report is an essential source of information and analysis on the German prostate cancer therapeutics market. The report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. It identifies and analyzes the key trends shaping and driving the German prostate cancer therapeutics market, and analyzes the treatment usage patterns. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global prostate cancer sector. It quantifies the unmet need in the German prostate cancer therapeutics market, highlighting the opportunity for future players. 

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts. 

Scope

The scope of the report includes: 

  • An overview of prostate cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized German prostate cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, forecast for 11 years to 2020. 
  • Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events. 
  • Competitor assessment including drug launch analysis and drug sales forecasts.
  • Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM (Life Cycle Management) activities and drug sales forecast.
  • Analysis of unmet need in the market and target product profiles including opportunity for target products. 
  • Technology trends analytic framework to assess the strength of the pipeline. 
  • Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, tyrosine kinase inhibitor, angiogenesis inhibitors and others.
  • An overview of the most promising drugs including clinical study details, efficacy, safety, collaboration agreements, marketing rights and launch analysis.
  • Analysis of the current and future market competition in the German Prostate Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Sanofi-aventis, Pfizer, Inc., AstraZeneca PLC, Bristol-Myers Squibb, Medivation, Takeda Pharmaceuticals and Dendreon Corporation.
  • Analysis of licensing agreements during 2004-2010 in the prostate cancer therapeutics market. Merger and Acquisition (M&A analysis) which includes M&A deals by size and geography.
  • Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
  • Direct quotes from key opinion leaders (KOL) or physicians in the prostate cancer therapeutics market in Germany.
Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop business strategies and perform superior market quantification analysis by 
  • Understanding the trends shaping and driving the German prostate cancer therapeutics market. 
  • Understanding the treatment preferences of physicians for each disease state and across treatment flow.
  • Accessing market sizing forecasts and quantified growth opportunities in the German prostate cancer therapeutics market up to 2020.
  • Quantifying the patient population in the German to better design product pricing and launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
  • Performing benchmarking analysis and growth opportunities against currently marketed products.
  • Identifying market entry points based on safety, efficacy, and pricing parameters. 
  • Assessing competitiveness of products in the market by understanding the strengths and weaknesses of current competition. 
  • Develop and design your in-licensing and out-licensing strategies by 
  • Taking a comprehensive look at the disease pipeline and identifying the most promising paradigm-shifting products.
  • Assessing the strength of pipeline based on first-in-class, me-too and generic products and their lifecycle management.
  • Track drug sales in the German prostate cancer therapeutics market from 2001 to 2020.
  • Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
  • Whats the next big thing in the German prostate cancer therapeutics market landscape? Identify, understand and capitalize.
Table of Content

1 Table of contents 4
1.1 List of Tables 7
1.2 List of Figures 8

2 Disease Overview 10
2.1 Overview 10
2.1.1 TNM (Tumor, Nodes, Metastasis) Staging System 10
2.1.2 Jewett-Whitmore system 11
2.2 Epidemiology 12
2.3 Etiology 12
2.4 Symptoms 12
2.4.1 Localized or Locally Advanced Prostate Cancer 12
2.4.2 Metastatic Prostate Cancer 13
2.5 Diagnosis 13
2.5.1 Digital Rectal Examination 13
2.5.2 Prostate Specific Antigen Test 13
2.5.3 Transrectal Ultrasound 14
2.5.4 Prostate Biopsy 14
2.6 Pathology 15
2.6.1 Grading 15
2.7 Treatment 15
2.7.1 Watchful Waiting 15
2.7.2 Radiation therapy 15
2.7.3 Surgery 16
2.7.4 Hormone therapy 17
2.7.5 Chemotherapy Options 18
2.7.6 Other Treatments Being Studied 19
2.8 Treatment Guidelines 19

3 Market Characterization 20
3.1 Germany 20
3.1.1 Market Size 20
3.1.2 Drivers and Barriers 26
3.1.3 Impact on the Market 28
3.1.4 Forecasts 29
3.1.5 Drug Sales 35
3.1.6 Pricing & Reimbursements 39

4 Competitor Assessment 40
4.1 Strategic Competitor Assessment 40
4.1.1 Overview 40
4.1.2 Benchmarking 40
4.1.3 Current Competitor Assessment 44
4.2 Launch Analysis and Sales Forecasts 45
4.3 Product Profiles 46
4.3.1 Taxotere (docetaxel) 47
4.3.2 Casodex (Bicalutamide) 50
4.3.3 Zoladex (Goserelin) 55
4.3.4 Eligard (leuprolide acetate) 57
4.3.5 Firmagon (degarelix) 62
4.3.6 Novantrone (Mitoxantrone hydrochloride) 64
4.3.7 Emcyt (estramustine) 66
4.3.8 Trelstar (triptorelin) 68
4.3.9 Eulexin 69
4.3.10 Delestrogen 71
4.3.11 Gynodiol 72
4.3.12 Estrace tablet 73
4.3.13 Tace 73
4.3.14 Nilandrone 74
4.3.15 Premarin 75
4.3.16 Sales Forecast for Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol 76

5 Pipeline Assessment 77
5.1 Overview 77
5.2 Pipeline Analysis by Phase of Development 78
5.3 Pipeline by Mechanism of Action 79
5.4 Strategic Pipeline Assessment 80
5.4.1 Technology Trends Analytical Framework 80
5.5 Trends in Prostate Cancer Pipeline 81
5.5.1 More Clarity on the Origin of Prostate Cancer Will Help in Identifying Novel Targets for Prostate Cancer Drugs 81
5.5.2 Molecules with Novel Mechanism of Action Strengthening Prostate Cancer Pipeline 81
5.5.3 Failure of Key Molecules to Achieve Positive Results in Phase III Development 81
5.6 Partners in Research and Development 82
5.6.1 Licensing Agreements by Phase of Development 82
5.6.2 Licensing Agreements by Geography 85
5.6.3 Licensing Agreements: Technology Licensing Agreements in Prostate Cancer 85
5.7 Most Promising Drugs Profiles 86
5.7.1 Provenge (sipuleucel-T) 87
5.7.2 Jevtana (cabazitaxel) 90
5.7.3 Aflibercept (VEGF Trap) 91
5.7.4 Ipilimumab 94
5.7.5 Abiraterone Acetate (CB7630) 96
5.7.6 Zibotentan (ZD4054) 98
5.7.7 Sprycel (dasatinib) 100
5.7.8 MDV3100 102
5.8 Prostate Cancer Pipeline Pre-clinical Phase 105
5.9 Prostate Cancer Pipeline Phase I 106
5.10 Prostate Cancer Pipeline Phase II 108
5.11 Prostate Cancer Pipeline Phase III 115
5.12 Key Takeaway 116

6 Unmet Need and Target Product Profile 117
6.1 Unmet Need 119
6.1.1 Hormone-independent Metastatic Prostate Cancer Therapy 119
6.1.2 Hormone-dependent Metastatic Prostate Cancer Therapy 120
6.2 Opportunity for Target Product 121
6.3 Target Product Profile 123
6.3.1 Ideal Characteristics 123
6.3.2 Target Product Description 124
6.4 Key Takeaway 124

7 Strategic Assessment 125
7.1 Key Events Impacting the Future Market 125
7.2 Market Impact Analysis 126
7.3 Future Market Scenario 126
7.4 Company Analysis 127
7.4.1 Market Leadership 127
7.4.2 Future Players in the Market 128
7.5 Key Takeaway 128

8 Company Profiles 129
8.1 Sanofi-aventis 129
8.1.1 Business Description 129
8.1.2 Financial Overview 131
8.1.3 SWOT Analysis 131
8.1.4 Oncology Focus 136
8.2 Pfizer Inc. 136
8.2.1 Business Description 136
8.2.2 Financial Overview 137
8.2.3 SWOT Analysis 138
8.2.4 Oncology Focus 144
8.3 AstraZeneca 145
8.3.1 Business Description 145
8.3.2 Financial Overview 147
8.3.3 SWOT Analysis 147
8.3.4 Oncology Focus 151
8.4 Bristol-Myers Squibb 152
8.4.1 Business Description 152
8.4.2 Financial Overview 153
8.4.3 SWOT Analysis 154
8.4.4 Oncology Focus 159
8.5 Medivation 160
8.5.1 Business Description 160
8.5.2 SWOT Analysis 161
8.5.3 Oncology Focus 164
8.6 Takeda Pharmaceuticals 164
8.6.1 Business Description 164
8.6.2 SWOT Analysis 165
8.7 Dendreon Corporation 166
8.7.1 Business Description 166
8.7.2 SWOT Analysis 167
8.8 Johnson and Johnson 170
8.8.1 Business Description 170
8.8.2 SWOT Analysis 171
8.8.3 Oncology Focus 178
8.9 Auron Healthcare GmbH 179
8.9.1 Business Description 179
8.10 Oncogenex Pharmaceuticals, Inc. 179
8.10.1 Business Description 179
8.11 Agennix AG 179
8.11.1 Business Description 179
8.12 GTx, Inc. 180
8.12.1 Business Description 180
8.13 GlaxoSmithKline plc. 180
8.13.1 Business Description 180
8.13.2 Financial Overview 181
8.13.3 SWOT Analysis 181
8.13.4 Oncology Focus 187

9 M&A Analysis 189
9.1 Key Highlights 189
9.2 Key Deals Analysis 190
9.2.1 Johnson & Johnson Acquires Cougar Biotechnology 190
9.2.2 Endo Pharmaceuticals Acquires Indevus Pharmaceuticals 190
9.2.3 Tolmar Holding Acquires QLT USA from QLT 191
9.2.4 Biomarin Pharmaceutical to Acquire Lead therapeutics 191
9.2.5 Isis Pharmaceuticals Reacquires Rights to Cancer Drug from Eli Lilly & Co. 191
9.2.6 Quest PharmaTech Acquires Late-stage Immunotherapeutic Antibody Pipeline from Paladin Labs 191
9.2.7 VaxOnco Acquires Rights to Onyvax-P Cell Vaccine From Onyvax 191
9.2.8 GPC Biotech Merges with Agennix 191
9.2.9 Eli Lilly Acquires ImClone 192
9.2.10 BBM Holdings Acquires YM BioSciences 192
9.2.11 Sagent Pharmaceuticals Acquires Injectable Generic Drug Applications of Spectrum Pharmaceuticals 192
9.3 M&A Deals by Geography 193
9.4 M&A Deals by Deal Size 193

10 Expert Opinion 194
10.1 Germany 194

11 Appendix 195
11.1 Market Definitions 195
11.2 Abbreviations 195
11.3 Research Methodology 197
11.3.1 Coverage 197
11.3.2 Secondary Research 198
11.3.3 Forecasting 198
11.3.4 Primary Research 201
11.3.5 Expert Panel validation 201
11.3.6 Contact Us 201
11.3.7 Disclaimer 201
11.3.8 Sources 202

List of Table


Table 1: Prostate Cancer Therapeutics Market, Global, Staging of the Prostate Cancer, 2010 11
Table 2: Prostate Cancer, Global, Age Related PSA Levels (ng/ml), 2010 14
Table 3: Prostate Cancer Therapeutics Market, Germany, Sales Value ($m), 2001-2009 20
Table 4: Prostate Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2001-2009 22
Table 5: Prostate Cancer Therapeutics Market, Germany, Patient Volume (000s), 2001-2009 23
Table 6: Prostate Cancer Therapeutics Market, Germany, Treatment Usage Patterns (000s), 2001-2009 24
Table 7: Prostate Cancer Therapeutics Market, Germany, Sales Value ($m), 2009-2020 29
Table 8: Prostate Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2009-2020 30
Table 9: Prostate Cancer Therapeutics Market, Germany, Patient Volume (000s), 2009-2020 31
Table 10: Prostate Cancer Therapeutics Market, Germany, Treatment Usage Patterns (000s), 2009-2020 32
Table 11: Prostate Cancer Therapeutics Market, Germany, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2010 36
Table 12: Prostate Cancer Therapeutics Market, Germany, Hormone-refractory Prostate Cancer Drug Sales ($m), 2011-2020 36
Table 13: Prostate Cancer Therapeutics Market, Germany, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2010 38
Table 14: Prostate Cancer, Germany, Hormone-dependent Prostate Cancer Drug Sales ($m), 2011-2020 38
Table 15: Prostate Cancer, Global, Clinical Endpoints for Benchmarking, 2010 41
Table 16: Prostate Cancer, Global, Chemotherapy, Safety Profile of Standard Care Treatment, 2010 42
Table 17: Prostate Cancer, Global, Hormone Therapy, Safety Profile of Standard Care Treatment, 2010 43
Table 18: Prostate Cancer, Germany, Benchmarking Major Marketed Products, 2010 46
Table 19: Prostate Cancer, Global, Casodex, Incidence of Adverse Effects, 2010 51
Table 20: Prostate Cancer, Global, Eligard, Effect on PSA Level, 2010 58
Table 21: Prostate Cancer, Global, Eligard, Incidence of Adverse Effects, 2010 59
Table 22: Prostate Cancer, Global, Eligard, Regulatory Approval by Region 60
Table 23: Prostate Cancer, Global, Licensing Agreements, 2009-2010 84
Table 24: Prostate Cancer, Global, Technology Licensing Agreements Description, 2010 86
Table 25: Prostate Cancer, Global, Most Promising Drugs Under Clinical Development, 2010 86
Table 26: Prostate Cancer, Global, Pre-clinical Phase Pipeline, August 2010 105
Table 27: Prostate Cancer, Global, Phase I Pipeline, August 2010 106
Table 28: Prostate Cancer, Global, Phase II Pipeline, August 2010 108
Table 29: Prostate Cancer, Global, Phase III Pipeline, August 2010 115
Table 30: Prostate Cancer, Global, Characteristics of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010 123
Table 31: Prostate Cancer, Global, Description of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010 124
Table 32: Prostate Cancer, Johnson & Johnson, Oncology Late Stage Pipeline by Indication, 2010 178
Table 33: Prostate Cancer, Global, Auron Healthcare, Key Pipeline Products, 2010 179
Table 34: Prostate Cancer, Global, M&A Deals by Geography, 2010 189

List of Chart


Figure 1: Prostate Cancer Therapeutics Market, Global, Treatment Guidelines, 2010 19
Figure 2: Prostate Cancer Therapeutics Market, Germany, Sales Value ($m), 2001-2009 20
Figure 3: Prostate Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2001-2009 21
Figure 4: Prostate Cancer Therapeutics Market, Germany, Patient Volume (000s), 2001-2009 23
Figure 5: Prostate Cancer Therapeutics Market, Germany, Treatment Usage Patterns (000s), 2001-2009 24
Figure 6: Prostate Cancer Therapeutics Market, Germany, Market Drivers and Restraints, 2009 26
Figure 7: Prostate Cancer Therapeutics Market, Germany, Historical Events Impact on the Market, 2010 28
Figure 8: Prostate Cancer Therapeutics Market, Germany, Sales Value ($m), 2009-2020 29
Figure 9: Prostate Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2009-2020 30
Figure 10: Prostate Cancer Therapeutics Market, Germany, Patient Volume (000s), 2009-2020 31
Figure 11: Prostate Cancer Therapeutics Market, Germany, Treatment Usage Patterns (000s), 2009-2020 32
Figure 12: Prostate Cancer Therapeutics Market, Germany, Future Market Drivers and Restraints, 2009-2020 34
Figure 13: Prostate Cancer Therapeutics Market, Germany, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2020 35
Figure 14: Prostate Cancer Therapeutics Market, Germany, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2020 37
Figure 15: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Chemotherapy Drugs, 2010 44
Figure 16: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Hormone Therapy Drugs, 2010 45
Figure 17: Prostate Cancer Therapeutics Market, Germany, Sales Forecast by Therapies, 2001-2020 46
Figure 18: Prostate Cancer, Global, Taxotere, Chemical Structure 48
Figure 19: Prostate Cancer, Global, Taxotere, LCM Activities, 2004-2010 49
Figure 20: Prostate Cancer, Germany, Taxotere, Sales ($m), 2004-2020 50
Figure 21: Prostate Cancer, Global, Casodex, Chemical Structure 51
Figure 22: Prostate Cancer, Global, Casodex, LCM Activities, 2004-2010 54
Figure 23: Prostate Cancer, Germany, Casodex, Sales ($m), 2001-2020 55
Figure 24: Prostate Cancer, Global, Zoladex, Chemical Structure 56
Figure 25: Prostate Cancer, Germany, Zoladex, Sales Forecast ($m), 2001-2020 57
Figure 26: Prostate Cancer, Global, Eligard , Chemical Structure 58
Figure 27: Prostate Cancer, Germany, Leuprolide (Eligard), Sales Forecast ($m), 2001-2020 61
Figure 28: Prostate Cancer, Global, Firmagon, Chemical Structure 62
Figure 29: Prostate Cancer, Germany, Firmagon, Sales Forecast ($m), 2008-2020 64
Figure 30: Prostate Cancer, Global, Novatrone, Chemical Structure 64
Figure 31: Prostate Cancer, Germany, Mitoxantrone, Sales Forecast ($m), 2001-2020 66
Figure 32: Prostate Cancer, Global, Emcyt, Chemical Structure 67
Figure 33: Prostate Cancer, Germany, Estramustine, Sales Forecast ($m), 2001-2020 67
Figure 34: Prostate Cancer, Global, Trelstar, Chemical Structure 68
Figure 35: Prostate Cancer, Global, Eulexin, Chemical Structure 69
Figure 36: Prostate Cancer, Global, Delestrogen, Chemical Structure 71
Figure 37: Prostate Cancer, Global, Gynodiol, Chemical Structure 72
Figure 38: Prostate Cancer, Global, Estrace, Chemical Structure 73
Figure 39: Prostate Cancer, Global, Tace, Chemical Structure 74
Figure 40: Prostate Cancer, Global, Nilandrone, Chemical Structure 74
Figure 41: Prostate Cancer, Global, Premarin, Chemical Structure 75
Figure 42: Prostate Cancer, Germany, Combined sales of Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol, Sales Forecast ($m), 2001-2020 76
Figure 43: Prostate Cancer, Global, Clinical Trials by Therapy, 2010 77
Figure 44: Prostate Cancer, Global, Clinical Trials by Phase of Development, 2010 78
Figure 45: Prostate Cancer, Global, Pipeline by Mechanism of Action, 2010 79
Figure 46: Prostate Cancer, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010 80
Figure 47: Prostate Cancer, Global, Technology Trends Description of Pipeline Drugs, 2010 81
Figure 48: Prostate Cancer, Global, Licensing Agreements by Phase of Development, 2009-2010 82
Figure 49: Prostate Cancer, Global, Licensing Agreements by Geography, 2010 85
Figure 50: Prostate Cancer, Germany, Provenge, Sales Forecast ($m), 2009-2020 89
Figure 51: Prostate Cancer, Germany, Jevtana, Sales Forecast ($m), 2001-2020 91
Figure 52: Prostate Cancer, Global, Aflibercept, Chemical Structure 92
Figure 53: Prostate Cancer, Germany, Aflibercept, Sales Forecast ($m), 2009-2020 93
Figure 54: Prostate Cancer, Germany, Ipilimumab , Sales Forecast ($m), 2009-2020 95
Figure 55: Prostate Cancer, Global, Abiraterone, Chemical Structure 96
Figure 56: Prostate Cancer, Germany, Abiraterone, Sales Forecast ($m), 2009-2020 98
Figure 57: Prostate Cancer, Global, Zibotentan, Chemical Structure 99
Figure 58: Prostate Cancer, Germany, Zibotentan , Sales Forecast ($m), 2009-2020 100
Figure 59: Prostate Cancer, Germany, Sprycel , Sales Forecast ($m), 2009-2020 102
Figure 60: Prostate Cancer, Global, MDV3100, Chemical Structure 103
Figure 61: Prostate Cancer, Germany, MDV3100 , Sales Forecast ($m), 2009-2020 104
Figure 62: Prostate Cancer, Global, Median Overall Survival for Hormone-independent Metastatic Prostate Cancer Patients, 2010 117
Figure 63: Prostate Cancer, Global, Median Overall Survival for Hormone-dependent Metastatic Prostate Cancer Patients, 2010 118
Figure 64: Prostate Cancer, Global, Hormone-dependent Metastatic Prostate Cancer Patients Achieving Castrate Level Testosterone Level in 28-30 Days (%), 2010 118
Figure 65: Prostate Cancer, Germany, Prostate Cancer, Opportunity and Unmet Need, 2010 119
Figure 66: Prostate Cancer, Germany, Hormone-independent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 122
Figure 67: Prostate Cancer, Germany, Hormone-dependent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 123
Figure 68: Prostate Cancer, Global, Key Events Impacting the Future Market 125
Figure 69: Prostate Cancer, Germany, Implications for Future Market Competition, 2010 126
Figure 70: Prostate Cancer, Global, Future Players in the Market, 2010 128
Figure 71:Prostate Cancer, Sanofi-aventis, Major Pharmaceutical Drugs 2010 129
Figure 72: Prostate Cancer, Sanofi-aventis Pasteur, Diseases Under Each Vaccination Area 2010 130
Figure 73: Prostate Cancer, Global, Sanofi-aventis, SWOT Analysis, 2010 131
Figure 74: Prostate Cancer, Sanofi-aventis, Therapeutic Segment Share of Pipeline 2010 136
Figure 75: Prostate Cancer, Global, Pfizer, SWOT Analysis 2010 138
Figure 76: Prostate Cancer, Pfizer, Distribution of Pipeline by Phase, 2010 144
Figure 77: Prostate Cancer, Pfizer, Therapeutic Segment Share of Pipeline 2010 145
Figure 78: Prostate Cancer, Astrazeneca, Key Products Portfolio 2010 146
Figure 79: Prostate Cancer, Global, AstraZeneca, SWOT Analysis 2010 147
Figure 80: Prostate Cancer, AstraZeneca, Oncology Products for Different Cancers 2010 151
Figure 81: Prostate Cancer, AstraZeneca, Distribution of Pipeline, by Phase, 2010 151
Figure 82: Prostate Cancer, AstraZeneca, Therapeutic Segment Share of Pipeline 2010 152
Figure 83: Prostate Cancer, Bristol-Myers Squibb, Key Products Portfolio 2010 153
Figure 84: Prostate Cancer, Global, Company Bristol-Myers Squibb, SWOT Analysis, 2010 154
Figure 85: Prostate Cancer, Bristol-Myers Squibb, Distribution of Pipeline by Phase, 2010 159
Figure 86: Prostate Cancer, Bristol-Myers Squibb, Therapeutic Segment Share of Pipeline 2010 160
Figure 87: Prostate Cancer, Global, Medivation, SWOT Analysis 2010 161
Figure 88: Prostate Cancer, Global, Takeda Pahrmaceuticals, SWOT Analysis 2010 165
Figure 89: Prostate Cancer, Global, Dendreon Corporation, SWOT Analysis 2010 167
Figure 90: Prostate Cancer, Global, Johnson and Johnson, SWOT Analysis 2010 172
Figure 91: Prostate Cancer, Johnson & Johnson, Late Stage Pipeline by Therapy Area, 2010 178
Figure 92: Prostate Cancer, Global, GlaxoSmithKline, SWOT Analysis 2010 181
Figure 93: Prostate Cancer, GlaxoSmithKline, Distribution of Pipeline by Phase, 2010 187
Figure 94: Prostate Cancer, GlaxoSmithKline, Therapeutic Segment Share of Pipeline 2010 188
Figure 95: Prostate Cancer, Global, M&A Deals by Geography of Target Companies, 2010 193
Figure 96: Prostate Cancer, Global, M&A Deals by Deal Size, 2010 193
Figure 97: Prostate Cancer, Germany, Key Data Inputs from KOL Interviews, July 2010 194
Figure 98: GlobalData Market Forecasting Model 200

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *